All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: HLX03
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Adalimumab is the third monoclonal antibody developed by Henlius and approved in China, after the Company's rituximab biosimilar HLX01, and trastuzumab biosimilar HLX02, the first China-developed mAb biosimilar approved both in China and in the EU.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Sulinno
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
SULINNO® (adalimumab injection) is a recombinant human anti-TNF-α monoclonal antibody drug approved by the china NMPA for the treatment of polyarticular juvenile idiopathic arthritis (pJIA). This is the fourth approved indication of SULINNO® in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Sulinno
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.